Optivida Health, Frelii in deal for DNA sequencing services

May 1, 2019 Off By BusinessWire

LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) today announced
that it has signed a contract and licensing agreement with Optivida
Health (Optivida), one of the nation’s leaders in advanced hemp extract
for the consumer market. Optivida will leverage Frelii’s proprietary DNA
Kit Packages™ to ensure Optivida customers can realize the optimal
benefits of which specific Optivida products best suit their unique DNA
profile.

“Historically, the only approach to using hemp extract, hemp oil, CBD
and other cannabinoid products effectively has been through trial and
error,” said Ian Jenkins, CEO of Frelii. “Now, through the power of
Frelii’s proprietary DNA Kit Packages, Optivida customers can have their
whole DNA sequenced and analyzed, whereby they will be given the ability
to know what hemp, CBD and other products are most appropriate and what
precision dose will work most effectively for their own specific needs.”

Frelii is a biotech company that specializes in providing a blend of
human DNA sequencing and Artificial Intelligence (AI), for the purpose
of assisting specific industries in advancing and providing personalized
care, pharmacogenetic alignment and wellness directives. With the
ability to sequence 3.2 billion markers of each individual’s DNA, Frelii
is able to provide the Health & Wellness, Healthcare and Pharmaceutical
industries with unique advanced data to aid in patient care, aid in
improved patient outcomes and recommendations to enhance an individual’s
general condition. Essentially, Frelii has the ability to recommend a
specific supplement or drug based on a person’s genetic profile and
need. Frelii can achieve this by using their proprietary AI to ensure
that the DNA report for each individual sequenced is optimized against
their own specific DNA markers, and those of millions of other similarly
aligned DNA profiles as reference, to ensure each recommendation is as
precision-based as possible in today’s market. Frelii recently launched
their DNA Kit Packages to the Health & Wellness industry. Similar, but
further enhanced versions of their offering will be available to the
healthcare and pharmaceutical industries soon.

Frelii is quite different from other DNA sequencing companies that
typically offer products to consumers for learning their heredity or
family ancestry. These types of companies only align an average of
500,000 DNA markers, which limits their ability to truly “see” the broad
palette of an individual’s DNA and issues that can influence their
health or treatment. With the ability to sequence billions of DNA
markers per person, Frelii can provide the individual or their care
provider with a much more comprehensive view of how their genetic
alignment may be influencing their current or future health.

Optivida customers will be able to purchase a customized, proprietary
Frelii DNA Kit Package. Following analysis by Frelii, customers will
receive personalized recommendations for their health and wellness via
the customized online report that the individual can access through a
highly secure online portal. This report will include specific health,
wellness, exercise, sleep and stress management recommendations for each
individual whose DNA was processed. Optivida’s products will be
integrated into the individual’s report so they know specifically which
products are ideal for them. This is a unique way for Optivida customers
to learn more about their own DNA, their health and wellness – as well
as how and which Optivida products will best help them achieve an
optimal health and wellness condition.

Optivida cultivates only top-quality strains of hemp, organically-grown
and naturally processed to exceed industry standards. Its Optisorb™ is
based on a liposomal technology that allows their hemp-based products to
be absorbed at an average of 17 times higher than competing products.
Furthermore, its products go under multiple layers of independent lab
quality and purity testing.

“Frelii’s technology makes a precise science out of getting the most
benefits from our supplements. When a customer gets the right amount of
the right nutrients, their body can begin to heal itself,” said Frank
Davis, CEO of Optivida Health. “It’s an incredible marriage of science,
biotechnology and nutrition. Our customers can be helped in a
revolutionary way. The combination of Frelii’s advanced DNA technology
matched with the best in patented and well-researched supplements gives
customers absolute assurance that they are getting the right amount of
the right nutrients to change their lives.”

About Optivida Health

Optivida Health (Optivida) is a company formed to continue the mission
of its founder and CEO, Frank Davis. Frank has been in the health and
wellness industry for over 30 years and is passionate and committed to
providing efficacious and uncompromising nutritional products for his
family, friends, and the people across the globe. Optivida is one of
North America’s leading providers of hemp extract. There is a unique
relationship between our cognizant selves and our endocannabinoid system
(ECS). This often not discussed basic human system is one of our many
fundamental physiological systems. The ECS is responsible for
maintaining homeostasis (balance) in the body. When this system isn’t
functioning properly, we start experiencing pain, sleep difficulties,
fatigue, and a whole host of other symptoms. When the ECS is supported
and working properly, each of these systems in the body works better.
The company does not sell any products containing THC. Cannabidiol (CBD)
is a natural component of hemp extract. Optivida hemp is a dietary
supplement. For more information, visit www.optividahealth.com.

About Frelii Inc.

Frelii Inc. is a biotech company that uses human DNA gene sequencing and
artificial intelligence (AI) to assess more than 3.2 billion markers on
the human genome. The results are aligned and leveraged against its AI,
as a means of creating a very strong and powerful data platform for use
by the Health & Wellness, Healthcare, Medical Cannabis and
Pharmaceutical industries. Frelii’s technology generates accurate and
profoundly valuable insight into an individual’s DNA. The company
provides DNA Kit Packages and customized reporting for consumers,
patients and healthcare providers to ensure the ideal treatment, drugs
and dosing are a prime “fit” to the individual. For more information,
please visit www.frelii.com.
Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage
and developing U.S. and international companies. Companies are current
in their reporting and undergo an annual verification and management
certification process. Investors can find Real-Time quotes and market
information for the company on www.otcmarkets.com.

Follow Frelii online at:

Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii
Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii
LinkedIn Page linkedin.com/company/frelii/

Safe Harbor Statement:

This release contains certain “forward-looking statements” relating to
the business of the Company. All statements, other than statements of
historical fact included herein are “forward-looking statements”
including statements regarding: the continued growth of the e-commerce
segment and the ability of the Company to continue its expansion into
that segment; the ability of the Company to attract customers and
partners and generate revenues; the ability of the Company to
successfully execute its business plan; the business strategy, plans,
and objectives of the Company; and any other statements of
non-historical information. These forward-looking statements are often
identified by the use of forward-looking terminology such as “believes,”
“expects” or similar expressions and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks, and uncertainties, and these expectations
may prove to be incorrect. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this news release. The Company’s actual results could differ materially
from those anticipated in these forward-looking statements as a result
of a variety of factors, including those discussed in the Company’s
periodic reports that are filed with the Securities and Exchange
Commission and available on its website (http://www.sec.gov).
All forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the Company
does not assume any duty to update these forward-looking statements.